Active Lifestyle Reduces Risk of Invasive Breast Cancer

Publication
Article
OncologyONCOLOGY Vol 21 No 5
Volume 21
Issue 5

Six or more hours per week of strenuous recreational activity may reduce the risks of invasive breast cancer by 23%

Six or more hours per week of strenuous recreational activity may reduce the risks of invasive breast cancer by 23%, according to researchers from the University of Wisconsin Paul P. Carbone Comprehensive Cancer Center (UWCCC). Their report in a recent issue of Cancer Epidemiology Biomarkers & Prevention, based on a survey of over 15,000 women, shows that exercise has a protective effect against invasive breast cancer throughout a woman's lifetime. The results provide further evidence that for most women, physical activity may reduce the risk of invasive breast cancer, the researchers concluded.

Detailed Phone Interviews

To gain further insights into the mechanisms of risk reduction for breast cancer, the researchers investigated the relationship between physical activity and breast cancer risk in a population-based case control study in Massachusetts, New Hampshire, and Wisconsin.

During structured telephone interviews, the researchers questioned 7,630 women without breast cancer, 1,689 survivors of in situ, or noninvasive, breast cancer and 6,391 survivors of invasive breast cancer, all between the ages of 20 and 69. They asked detailed questions about physical activity, occupation, family history of breast cancer, menopausal status, and body mass index.

According to the researchers, women who exercised had a reduced risk of developing invasive breast cancer provided they didn't have a family history of breast cancer. This reduction in risk was apparent whether the physical activity took place early in life, in the postmenopausal years, or in the recent past.

"A woman's hormone levels naturally fluctuate throughout her life, and we have found that exercise likely offers protection against breast cancer regardless of a woman's stage in life," said Brian Sprague, a UWCCC research assistant and lead author of the study. "The take-home message for women should be that it is never too late to begin exercising."

Related Videos
Sara M. Tolaney, MD, MPH, an expert on breast cancer
Sara M. Tolaney, MD, MPH, an expert on breast cancer
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Ann H. Partridge, MD, MPH, talks about how fertility preservation can positively impact the psychosocial health in patients with breast cancer.
Daniel G. Stover, MD, describes how findings from the phase 3 NATALEE trial may support expanding the portion of patients who receive CDK 4/6 inhibitors as a treatment for hormone receptor–positive, HER2-negative breast cancer.
Daniel G. Stover, MD, suggests that stromal tumor infiltrating lymphocytes may serve as a biomarker of immune activation and can potentially help optimize therapy with microtubule-targeting agents for patients with metastatic breast cancer.
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
An expert from Dana-Farber Cancer Institute describes which patients hormone receptor-positive,  HER2-negative breast cancer will benefit most from treatment with sacituzumab govitecan.
Related Content